WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Changes to oral drug bioavailability have been observed post bariatric surgery. However, the magnitude and the direction of changes have not been assessed systematically to provide insights into the parameters governing the observed trends. Understanding these can help with dose adjustments. WHAT THIS STUDY ADDS: Analysis of drug characteristics based on a biopharmaceutical classification system is not adequate to explain observed trends in altered oral drug bioavailability following bariatric surgery, although the findings suggest solubility to play an important role. AIMS: To identify the most commonly prescribed drugs in a bariatric surgery population and to assess existing evidence regarding trends in oral drug bioavailability post bariatric surgery. METHODS: A retrospective audit was undertaken to document commonly prescribed drugs amongst patients undergoing bariatric surgery in an NHS hospital in the UK and to assess practice for drug administration following bariatric surgery. The available literature was examined for trends relating to drug permeability and solubility with regards to the Biopharmaceutics Classification System (BCS) and main route of elimination. RESULTS: No significant difference in the 'post/pre surgery oral drug exposure ratio' (ppR) was apparent between BCS class I to IV drugs, with regards to dose number (Do) or main route of elimination. Drugs classified as 'solubility limited' displayed an overall reduction as compared with 'freely soluble' compounds, as well as an unaltered and increased ppR. CONCLUSION: Clinical studies establishing guidelines for commonly prescribed drugs, and the monitoring of drugs exhibiting a narrow therapeutic window or without a readily assessed clinical endpoint, are warranted. Using mechanistically based pharmacokinetic modelling for simulating the multivariate nature of changes in drug exposure may serve as a useful tool in the further understanding of postoperative trends in oral drug exposure and in developing practical clinical guidance.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Changes to oral drug bioavailability have been observed post bariatric surgery. However, the magnitude and the direction of changes have not been assessed systematically to provide insights into the parameters governing the observed trends. Understanding these can help with dose adjustments. WHAT THIS STUDY ADDS: Analysis of drug characteristics based on a biopharmaceutical classification system is not adequate to explain observed trends in altered oral drug bioavailability following bariatric surgery, although the findings suggest solubility to play an important role. AIMS: To identify the most commonly prescribed drugs in a bariatric surgery population and to assess existing evidence regarding trends in oral drug bioavailability post bariatric surgery. METHODS: A retrospective audit was undertaken to document commonly prescribed drugs amongst patients undergoing bariatric surgery in an NHS hospital in the UK and to assess practice for drug administration following bariatric surgery. The available literature was examined for trends relating to drug permeability and solubility with regards to the Biopharmaceutics Classification System (BCS) and main route of elimination. RESULTS: No significant difference in the 'post/pre surgery oral drug exposure ratio' (ppR) was apparent between BCS class I to IV drugs, with regards to dose number (Do) or main route of elimination. Drugs classified as 'solubility limited' displayed an overall reduction as compared with 'freely soluble' compounds, as well as an unaltered and increased ppR. CONCLUSION: Clinical studies establishing guidelines for commonly prescribed drugs, and the monitoring of drugs exhibiting a narrow therapeutic window or without a readily assessed clinical endpoint, are warranted. Using mechanistically based pharmacokinetic modelling for simulating the multivariate nature of changes in drug exposure may serve as a useful tool in the further understanding of postoperative trends in oral drug exposure and in developing practical clinical guidance.
Authors: C Becker; J B Dressman; G L Amidon; H E Junginger; S Kopp; K K Midha; V P Shah; S Stavchansky; D M Barends Journal: J Pharm Sci Date: 2008-04 Impact factor: 3.534
Authors: I B Skottheim; K Stormark; H Christensen; G S Jakobsen; J Hjelmesaeth; T Jenssen; J L E Reubsaet; R Sandbu; A Asberg Journal: Clin Pharmacol Ther Date: 2009-06-03 Impact factor: 6.875
Authors: J Picot; J Jones; J L Colquitt; E Gospodarevskaya; E Loveman; L Baxter; A J Clegg Journal: Health Technol Assess Date: 2009-09 Impact factor: 4.014
Authors: Pieter Colin; Douglas J Eleveld; Michel M R F Struys; Huybrecht T'Jollyn; Luc M Van Bortel; Johannes Ruige; Jan De Waele; Jan Van Bocxlaer; Koen Boussery Journal: Br J Clin Pharmacol Date: 2014-07 Impact factor: 4.335
Authors: Renata V A Collares-Pelizaro; José S Santos; Carla B Nonino; Larissa Alves dos Reis Dias; Cristiane M Gaitani; Wilson Salgado Journal: Obes Surg Date: 2017-09 Impact factor: 4.129
Authors: A S Darwich; D Pade; K Rowland-Yeo; M Jamei; A Asberg; H Christensen; D M Ashcroft; A Rostami-Hodjegan Journal: CPT Pharmacometrics Syst Pharmacol Date: 2013-06-12
Authors: Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe Journal: Br J Clin Pharmacol Date: 2021-06-03 Impact factor: 3.716
Authors: Jøran Hjelmesæth; Anders Åsberg; Shalini Andersson; Rune Sandbu; Ida Robertsen; Line Kristin Johnson; Philip Carlo Angeles; Jens Kristoffer Hertel; Eva Skovlund; Maria Heijer; Anna-Lena Ek; Veronica Krogstad; Tor-Ivar Karlsen; Hege Christensen; Tommy B Andersson; Cecilia Karlsson Journal: BMJ Open Date: 2018-05-29 Impact factor: 2.692
Authors: Felix Piecha; Jan-Michael Gänßler; Sabine Jordan; Can Ergen; Harald Ittrich; Johannes Kluwe; Sven Pischke; Ansgar W Lohse; Julian Schulze Zur Wiesch Journal: Hepatol Commun Date: 2019-03-18